2010-2015年与2015-2020年皮肤科临床试验多样性变化的评估:一项系统综述
该系统综述纳入392项2015年7月1日至2020年7月1日发表的美国随机临床试验,比较2010-2015年与2015-2020年皮肤科临床试验中患者性别、种族和民族多样性的变化。结果显示,种族和民族报告率从59.8%升至71.9%(P=0.05),但包含至少20%非白人受试者的报告文章比例仍为38.1%(2010-2015年97项中37项 vs 2015-2020年139项中53项,P=0.99)。银屑病研究的多样性最低,仅12.1%的研究记录了至少20%非白人受试者,29.5%的研究记录了至少45%女性受试者。
要点
- 2015-2020年美国皮肤科随机临床试验中种族和民族报告率较2010-2015年提高(59.8% vs 71.9%,P=0.05)。
- 包含至少20%非白人受试者的报告比例未变,仍为38.1%(2010-2015年37/97 vs 2015-2020年53/139,P=0.99)。
- 银屑病研究多样性最低:12.1%的研究有至少20%非白人受试者,29.5%的研究有至少45%女性受试者。
核心结论
- 系统综述提示,自2010-2015年以来,种族和民族数据的报告变得更加透明。
- 代表性患者人群的纳入可能仍被认为不足,尤其是在银屑病研究中。
- 临床试验的多样性对于代表受影响患者人群很重要,需要额外努力支持这一目标。
研究设计与样本
- 通过PubMed数据库对2015年7月1日至2020年7月1日发表的随机临床试验进行系统文献综述。
- 检索关键词包括斑秃、痤疮、特应性皮炎、扁平苔藓、银屑病、脂溢性皮炎和白癜风。
- 共纳入392项随机临床试验。
- 参照美国人口普查数据,种族和民族多样性不足定义为纳入少于20%的种族或民族多样性受试者,性别多样性不足定义为纳入少于45%的女性。
- 使用Python通过χ2检验或Fisher精确检验进行统计分析。
主要发现
- 与美国2010-2015年期间相比,美国研究中种族和民族的报告率从59.8%增加到71.9%(P=0.05)。
- 包含至少20%非白人代表的报告文章比例保持不变,为38.1%;2010-2015年97项报告随机临床试验中37项,2015-2020年139项报告随机临床试验中53项(P=0.99)。
- 银屑病研究多样性最低,12.1%的研究记录了至少20%非白人受试者,29.5%的研究记录了至少45%女性受试者。
关键数值与推荐
- 种族和民族多样性不足:纳入少于20%的种族或民族多样性受试者。
- 性别多样性不足:纳入少于45%的女性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although there have been increased efforts in dermatologic research to improve representation of patient sex, race, and ethnicity, there are limited data evaluating resulting changes. OBJECTIVE: To characterize the diversity of participants in dermatologic clinical trials conducted in the US published from 2015 to 2020 pertaining to common dermatologic conditions affecting all patient demographic categories compared with findings from 2010-2015. EVIDENCE REVIEW: A systematic literature review through the PubMed database was conducted for randomized clinical trials published between July 1, 2015, and July 1, 2020, using keywords alopecia areata, acne, atopic dermatitis, lichen planus, psoriasis, seborrheic dermatitis, and vitiligo. Data collected included distribution of participant demographic characteristics, funding source, and journal type. Reflecting US Census data, studies were defined as unrepresentative of race and ethnicity if they included less than 20% ethnically or racially diverse participants or unrepresentative of sex if they included less than 45% women. Python was used for statistical analysis by χ2 tests or Fisher exact tests. FINDINGS: A total of 392 randomized clinical trials were included. In comparison with the period from 2010-2015, the reporting rate for race and ethnicity in US studies has increased from 59.8% to 71.9% (P = .05). However, the proportion of reporting articles including at least 20% non-White representation remains unchanged at 38.1% with 37 of 97 reporting randomized clinical trials in 2010-2015 and 53 of 139 reporting randomized clinical trials in 2015-2020 (P = .99). Psoriasis studies included the least diversity, with 12.1% of studies recording at least 20% non-White participants and 29.5% of studies recording at least 45% female participants. CONCLUSIONS AND RELEVANCE: The findings of this systematic review suggest that reporting racial and ethnic data since 2010-2015 has become more transparent. However, inclusion of representative patient populations may still be considered inadequate, particularly in psoriasis studies. Diversity in clinical trials is important for representation of the affected patient populations, and additional efforts are warranted in support of this endeavor.
引用
- Chen V, Akhtar S, Zheng C, et al. Assessment of Changes in Diversity in Dermatology Clinical Trials Between 2010-2015 and 2015-2020: A Systematic Review. JAMA Dermatol. 2022. PMID: 35080592. doi:10.1001/jamadermatol.2021.5596
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。